RT Journal Article
SR Electronic
T1 Travel-driven emergence and spread of SARS-CoV-2 lineage B.1.620 with multiple VOC-like mutations and deletions in Europe
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.04.21256637
DO 10.1101/2021.05.04.21256637
A1 Dudas, Gytis
A1 Hong, Samuel L.
A1 Potter, Barney
A1 Calvignac-Spencer, Sébastien
A1 Niatou-Singa, Frédéric S.
A1 Tombolomako, Thais B.
A1 Fuh-Neba, Terence
A1 Vickos, Ulrich
A1 Ulrich, Markus
A1 Leendertz, Fabian H.
A1 Khan, Kamran
A1 Watts, Alexander
A1 Olendraitė, Ingrida
A1 Snijder, Joost
A1 Wijnant, Kim N.
A1 Bonvin, Alexandre M.J.J.
A1 Martres, Pascale
A1 Behillil, Sylvie
A1 Ayouba, Ahidjo
A1 Maidadi, Martin Foudi
A1 Djomsi, Dowbiss Meta
A1 Godwe, Celestin
A1 Butel, Christelle
A1 Šimaitis, Aistis
A1 Gabrielaitė, Miglė
A1 Katėnaitė, Monika
A1 Norvilas, Rimvydas
A1 Raugaitė, Ligita
A1 Jonikas, Rimvydas
A1 Nasvytienė, Inga
A1 Žemeckienė, Živilė
A1 Gečys, Dovydas
A1 Tamušauskaitė, Kamilė
A1 Norkienė, Milda
A1 Vasiliūnaitė, Emilija
A1 Žiogienė, Danguolė
A1 Timinskas, Albertas
A1 Šukys, Marius
A1 Šarauskas, Mantas
A1 Alzbutas, Gediminas
A1 Juozapaitė, Dovilė
A1 Naumovas, Daniel
A1 Pautienius, Arnoldas
A1 Vitkauskienė, Astra
A1 Ugenskienė, Rasa
A1 Gedvilaitė, Alma
A1 Čereškevičius, Darius
A1 Lesauskaitė, Vaiva
A1 Žemaitis, Lukas
A1 Griškevičius, Laimonas
A1 Baele, Guy
YR 2021
UL http://medrxiv.org/content/early/2021/05/08/2021.05.04.21256637.abstract
AB Many high-income countries have met the SARS-CoV-2 pandemic with overwhelming sequencing resources and have identified numerous distinct lineages, including some with notably altered biology. Over a year into the pandemic following unprecedented reductions in worldwide human mobility, distinct introduced lineages of SARS-CoV-2 without sequenced antecedents are increasingly discovered in high-income countries as a result of ongoing SARS-CoV-2 genomic surveillance initiatives. We here describe one such SARS-CoV-2 lineage, carrying many mutations and deletions in the spike protein shared with widespread variants of concern (VOCs), including E484K, S477N and deletions HV69Δ, Y144Δ, and LLA241/243Δ. This lineage – designated B.1.620 – is known to circulate in Lithuania and has now been found in several European states, but also in increasing numbers in central Africa owing to important recent increases in genome sequencing efforts on the continent. We provide evidence of likely ongoing local transmission of B.1.620 in Lithuania, France, Germany, Spain, Belgium and the Central African Republic. We describe the suite of mutations this lineage carries, its potential to be resistant to neutralising antibodies, travel histories for a subset of the European cases, and evidence of local B.1.620 transmission in Europe. We make a case for the likely Central African origin of this lineage by providing travel records as well as the outcomes of carefully crafted phylogenetic and phylogeographic inference methodologies, the latter of which is able to exploit individual travel histories recorded for infected travellers having entered different European countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSLH acknowledges support from the Research Foundation - Flanders ("Fonds voor Wetenschappelijk 501 Onderzoek - Vlaanderen," G0D5117N). BP and GB acknowledges support from the Internal Fondsen KU 502 Leuven/Internal Funds KU Leuven (Grant No. C14/18/094). GB acknowledges support from the Research 503 Foundation - Flanders ("Fonds voor Wetenschappelijk Onderzoek - Vlaanderen," G0E1420N, G098321N). 504 FHL and TFN were supported by WWF and German Research Council's grant LE1813/14-1 (Great Ape 505 Health in Tropical Africa), Research in CAR took place under permit #098/MRSIT/DIRCAB/CB.20, 506 granted to TT by the Ministery of Scientific Research and Technological Innovation. JS acknowledges 507 funding from the Dutch Research Council NWO Gravitation 2013 BOO, Institute for Chemical Immunol- 508 ogy (ICI; 024.002.009). AMJJB acknowledges the support of European Union Horizon 2020 projects 509 BioExcel (823830) and EOSC-Hub (777536) projects. AA and CB acknowledge the support of the French 510 National Research Institute for Sustainable Development (IRD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Lithuanian Bioethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData allowed to be distributed and scripts to reproduce analyses and figures are available at https://github.com/evogytis/B.1.620-in-Europe https://github.com/evogytis/B.1.620-in-Europe